|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Seizures, mixed pattern |
|
Neuralgia, glossopharyngeal |
|
Neuralgia, trigeminal |
|
Seizures, complex partial |
|
Seizures, generalized tonic- clonic |
| |
|
|
SIDE EFFECTS:
|
|
porphyria, acute intermittent |
|
pulmonary hypersensitivity |
|
thrombophlebitis |
|
Clumsiness or unsteadiness |
|
confusion |
|
dizziness, mild , or lightheadedness |
|
drowsiness, mild |
|
nausea or vomiting, mild |
|
Aching joints or muscles, or leg cramps |
|
alopecia |
|
anorexia |
|
constipation |
|
diaphoresis |
|
diarrhea |
|
dryness of mouth |
|
glossitis or stomatitis |
|
headache |
|
increased sensitivity of skin to sunlight |
|
sexual problems in males |
|
stomach pain or discomfort |
|
unusual tiredness or weakness |
|
CNS toxicity , including blurred or double vision |
|
nystagmus |
|
Allergic reaction |
|
Stevens-Johnson syndrome |
|
toxic epidermal necrolysis |
|
behavioral changes |
|
diarrhea, severe |
|
hyponatremia , dilutional, or water intoxication (SIADH) |
|
systemic lupus erythematosus (SLE)-like syndrome |
|
Adenopathy or lymphadenopathy |
|
blood dyscrasias, including aplastic anemia |
|
agranulocytosis |
|
eosinophilia |
|
leukopenia |
|
pancytopenia |
|
thrombocytopenia |
|
bone marrow depression |
|
cardiovascular effects, including arrhythmias |
|
atrioventricular (AV) heart block |
|
bradycardia |
|
congestive heart failure |
|
edema |
|
hypertension, increased |
|
hypotension |
|
syncope |
|
CNS toxicity |
|
hypersensitivity hepatitis |
|
hypocalcemia |
|
renal toxicity, renal failure, acute, or water intoxication (SIADH) |
|
paresthesias or peripheral neuritis |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Alcoholism, active |
|
Behavioral disorders |
|
Cardiac damage, includingngestive heart disease |
|
Coronary artery disease |
|
Diabetes mellitus |
|
Glaucoma |
|
Increased intraocular pressure |
|
Hematologic reactions, adverse, to other medications |
|
Hepatic function impairment |
|
Hyponatremia, dilutional, caused by syndrome of inappropriate antidiuretic hormone secretion |
|
Urinary retention |
|
Renal function impairment |
|
Sensitivity to carbamazepine or to tricyclic antidepressants |
|
|
ADULT DOSE:
|
|
Anticonvulsant-Initial: Oral, 200 mg two times a day on the first day, the dosage being increased by up to 200 mg a day at weekly intervals until the best response is obtained. Some clinicians recommend initiating therapy at 100 mg a day and increasing to full therapeutic dosage slowly at weekly intervals to avoid side effects and potential noncompliance.
Maintenance: Oral, adjusted to the minimum effective dosage, usually 600 mg to 1.6 grams a day.
Antineuralgic-Initial: Oral, 100 mg two times a day on the first day, the dosage being increased by up to 200 mg a day, using increments of 100 mg every twelve hours only as needed until pain is relieved.
Maintenance: Oral, 200 mg to 1.2 grams a day (average 400 to 800 mg a day) in divided doses.
[Antidiuretic] -Oral, 300 to 600 mg a day if used as sole therapy; or 200 to 400 mg a day if used concurrently with other antidiuretic agents.
[Antimanic] or
[Antipsychotic] -Oral, initially 200 to 400 mg a day in divided doses, the dosage being gradually increased at weekly intervals up to a maximum of 1.6 grams a day as needed and tolerated according to clinical response.
Note: Whenever possible, total daily dosage should be given in 3 or 4 divided doses. |
|
MAXIMUM ADULT DOSE:
|
|
Anticonvulsant-Patients 12 to 15 years of age-
Dosage should generally not exceed 1 gram a day.
Patients 15 years of age and over-
Dosage should generally not exceed 1.2 grams a day. In rare instances, doses of up to 1.6 grams a day have been used in adults.
Antineuralgic-Dosage should not exceed 1.2 grams a day. |
|
PEDIATRIC DOSE:
|
|
Anticonvulsant-Children up to 6 years of age -
Initial-Oral, 10 to 20 mg per kg of body weight a day in two or three divided doses, the dosage being increased by up to 100 mg a day at weekly intervals as needed and tolerated.
Maintenance-Oral, adjusted to the minimum effective dosage, usually 250 to 350 mg a day, and generally not exceeding 400 mg or 35 mg per kg of body weight a day.
Children 6 to 12 years of age-
Initial-Oral, 100 mg two times a day on the first day, the dosage being increased by 100 mg a day at weekly intervals until the best response is obtained.
Maintenance-Oral, adjusted to the minimum effective dosage, usually 400 to 800 mg a day.
Note: Dosage generally should not exceed 1 gram a day.
Whenever possible, total daily dosage should be given in 3 or 4 divided doses. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|